A Form 4 filed on September 16, 2026 with the U.S. Securities and Exchange Commission discloses that Aparna Bawa, a director of Palo Alto Networks Inc. (NASDAQ:PANW), sold a total of 1,500 shares of common stock across two transactions on September 14 and September …
Director John P. Key filed a Form 4 with the SEC on September 16, 2026, disclosing the sale of 2,500 shares of Palo Alto Networks Inc common stock on September 14, 2026.
A statement of changes in beneficial ownership filed on September 16, 2026 discloses that Ernesto Perez, a director of FrontView REIT, Inc. (NYSE:FVR), acquired 916 restricted stock units on September 15, 2026 at a price of $0.
A beneficial ownership change report for FrontView REIT, Inc. (NYSE:FVR) was filed on September 16, 2026, disclosing a grant of 705 LTIP Units to director Timothy McHugh on September 15, 2026.
A Form 4 filed on September 16, 2026 discloses that Anne M. Liddy, Chief Legal Officer of LivaNova PLC (NASDAQ:LIVN), was granted 6,291 restricted stock units on September 15, 2026.
A Form 4 filed on September 16, 2026, discloses that Robert S. Green, a director of FrontView REIT, Inc. (NYSE:FVR), acquired 705 restricted stock units on September 15, 2026, under the company's 2024 Omnibus Equity and Incentive Plan.
Christopher Tatnall, Executive Vice President of Global Customer Operations at Axcelis Technologies Inc., filed a Form 4 on September 16, 2026, reporting a disposition of common stock on September 15, 2026, related to the vesting of restricted stock units.
Greg Redinbo, EVP and Chief Strategy Officer of Axcelis Technologies Inc., filed a Form 4 on September 16, 2026, disclosing a disposition of common stock on September 15, 2026, related to the vesting of restricted stock units.
Nikhil Lalwani, President and CEO of ANI Pharmaceuticals Inc (NASDAQ:ANIP), filed a Form 4 on September 16, 2026, reporting the sale of 5,400 shares of common stock on September 15, 2026.
Director James R. Tobin filed a Form 4 with the SEC on September 16, 2026, reporting the exercise of two stock option grants and the subsequent sale of 30,000 shares of Globus Medical Class A Common Stock on September 15, 2026.